Abbott Increases Quarterly Dividend to 63 Cents, Marking 54th Consecutive Year of Growth
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 1 hour ago0mins
- Dividend Increase: Abbott has raised its quarterly dividend to 63 cents per share, reflecting a 6.8% increase, which not only showcases the company's robust profitability but also enhances investor confidence, likely attracting more long-term investors.
- Historical Achievement: The quarterly dividend has increased by over 70% since 2020, marking a strong commitment to shareholder returns and further solidifying Abbott's leadership position in the healthcare sector.
- Consistent Payments: This dividend marks Abbott's 408th consecutive payment since 1924, demonstrating the company's ability to maintain stable cash flow and profitability amid economic fluctuations, thereby enhancing its reputation as a member of the S&P 500 Dividend Aristocrats Index.
- Future Outlook: The dividend will be payable on February 13, 2026, to shareholders of record as of January 15, 2026, which is expected to further enhance the company's attractiveness in the healthcare sector and support its long-term growth strategy.
ABT.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABT is 147.24 USD with a low forecast of 136.00 USD and a high forecast of 162.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 123.280
Low
136.00
Averages
147.24
High
162.00
Current: 123.280
Low
136.00
Averages
147.24
High
162.00
Jefferies
Jefferies
Buy
to
Hold
downgrade
$90 -> $105
2025-11-24
Reason
Jefferies
Jefferies
Price Target
$90 -> $105
2025-11-24
downgrade
Buy
to
Hold
Reason
Jefferies downgraded Exact Sciences (EXAS) to Hold from Buy with a price target of $105, up from $90, citing the pending acquisition by Abbott (ABT). The firm thinks the takeover premium represents a win for Exact Sciences and does not expect another bidder to come over the top given precedent deal multiples.
Barclays
Overweight
maintain
$159 -> $162
2025-10-17
Reason
Barclays
Price Target
$159 -> $162
2025-10-17
maintain
Overweight
Reason
Barclays raised the firm's price target on Abbott to $162 from $159 and keeps an Overweight rating on the shares. The firm recommends using the pullback following the in-line Q3 report as a buying opportunity. The shares were discounting a slightly stronger beat for Q3, the analyst tells investors in a research note. Barclays views the business weakness as temporary, and expects Abbott's portfolio to return to growth toward the high end of its historical ranges in 2026 and beyond.
Wells Fargo
Overweight
maintain
$142 -> $146
2025-10-16
Reason
Wells Fargo
Price Target
$142 -> $146
2025-10-16
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Abbott to $146 from $142 and keeps an Overweight rating on the shares. The firm notes the company reported about in-line Q3 sales and EPS on Nutrition and China Dx headwinds, offset by Medtech and EPD strength. Abbott reiterated 2025 organic sales growth and tightened its EPS guide. The company is comfortable with prior 2026 Street estimates, Wells adds.
Raymond James
Outperform
maintain
$141 -> $146
2025-10-16
Reason
Raymond James
Price Target
$141 -> $146
2025-10-16
maintain
Outperform
Reason
Raymond James raised the firm's price target on Abbott to $146 from $141 and keeps an Outperform rating on the shares. Despite organic revenue growth and EPS that hit consensus, there was an expectation for more, and while Med Devices is accelerating, the rest of the business is experiencing some lumpiness, the analyst tells investors in a research note. The firm continues to see a 7%-8% organic revenue grower capable of growing 10%+ on the bottom-line.
See All Ratings
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What are the key factors influencing ETF inflows and outflows?
How does Abbott's FreeStyle Libre 3 sensor differ from other glucose monitors?
Will Abbott's acquisition of Exact Sciences improve its position in cancer diagnostics?
How might the FDA safety alert impact Abbott's future product sales?